

Andrew H Wei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5991230/publications.pdf>

Version: 2024-02-01

272
papers

26,478
citations

28736

57
h-index

7836

155
g-index

281
all docs

281
docs citations

281
times ranked

22372
citing authors

#	ARTICLE	IF	CITATIONS
1	Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. <i>Blood</i> , 2023, 141, 156-167.	0.6	27
2	Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. <i>Blood</i> , 2022, 139, 1198-1207.	0.6	34
3	Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 236-250.	0.2	10
4	Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system. <i>Leukemia Research</i> , 2022, 112, 106748.	0.4	2
5	Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death. <i>Cancer Discovery</i> , 2022, 12, 774-791.	7.7	18
6	Evolution of Therapy for Older Patients With Acute Myeloid Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> 19 BT / Overlock 10 T	1.9	2
7	Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. <i>Blood</i> , 2022, 139, 2145-2155.	0.6	38
8	Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy. <i>Hematological Oncology</i> , 2022, 40, 269-279.	0.8	13
9	Impact of FLT3-LT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 2744-2752.	3.2	43
10	Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML. <i>Cancer Discovery</i> , 2022, 12, 1560-1579.	7.7	13
11	Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2022, 63, 463-467.	0.6	13
12	Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 71.	2.8	12
13	Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial. <i>Blood Advances</i> , 2022, , .	2.5	13
14	Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2022, , .	1.2	0
15	Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms. <i>American Journal of Hematology</i> , 2022, 97, 1013-1022.	2.0	7
16	Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. <i>Blood Advances</i> , 2022, 6, 3879-3883.	2.5	25
17	Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	5
18	Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 568-583.	1.8	10

#	ARTICLE	IF	CITATIONS
19	Overall survival by <i>IDH2</i> mutant allele (R140 or R172) in patients with late-stage mutant- <i>IDH2</i> relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7005-7005.	0.8	3
20	Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7068-TPS7068.	0.8	0
21	Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic. <i>Leukemia and Lymphoma</i> , 2022, 63, 2731-2734.	0.6	0
22	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. <i>Blood</i> , 2022, 140, 1200-1228.	0.6	814
23	Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant- <i>IDH2</i> relapsed or refractory acute myeloid leukemia (R/R AML).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7032-7032.	0.8	0
24	Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. <i>Blood</i> , 2022, 140, 1345-1377.	0.6	805
25	The Patientsâ€™ Perspective: Hematological Cancer Patientsâ€™ Experiences of Adverse Events as Part of Care. <i>Journal of Patient Safety</i> , 2021, 17, e387-e392.	0.7	9
26	Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. <i>Leukemia</i> , 2021, 35, 62-74.	3.3	63
27	Venetoclax induces rapid elimination of <i>NPM1</i> mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 192, 1026-1030.	1.2	63
28	Outcomes and health care utilization of older patients with acute myeloid leukemia. <i>Journal of Geriatric Oncology</i> , 2021, 12, 243-249.	0.5	6
29	Double trouble or a silver lining? A case report of two patients with NPM1-mutated donor-derived acute myeloid leukemia (AML). <i>Leukemia and Lymphoma</i> , 2021, 62, 489-491.	0.6	0
30	Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative. <i>Pathology</i> , 2021, 53, 487-492.	0.3	0
31	Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. <i>American Journal of Hematology</i> , 2021, 96, 208-217.	2.0	95
32	Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2021, 11, 1582-1599.	7.7	35
33	Future Developments: Novel Agents. <i>Hematologic Malignancies</i> , 2021, , 293-315.	0.2	1
34	Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. <i>Leukemia</i> , 2021, 35, 2220-2231.	3.3	20
35	When Azoles Cannot Be Used: The Clinical Effectiveness of Intermittent Liposomal Amphotericin Prophylaxis in Hematology Patients. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab113.	0.4	8
36	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021, 35, 2539-2551.	3.3	51

#	ARTICLE	IF	CITATIONS
37	Taking aim at IDH in fitter patients with AML. <i>Blood</i> , 2021, 137, 1706-1707.	0.6	0
38	Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7011-7011.	0.8	3
39	Comparison of dose modification strategies to address expected hematologic toxicities in treatment-naïve higher-risk (HR) MDS patients treated with venetoclax + azacitidine.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7041-7041.	0.8	0
40	Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. <i>Blood</i> , 2021, 137, 2721-2735.	0.6	75
41	Towards precision medicine for AML. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 577-590.	12.5	138
42	Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) IDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7006-7006.	0.8	8
43	COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. <i>Internal Medicine Journal</i> , 2021, 51, 763-768.	0.5	12
44	Fitness for intensive chemotherapy: a continuing conundrum. <i>Blood</i> , 2021, 138, 356-358.	0.6	1
45	Estimating the Productivity Impact of Acute Myeloid Leukemia in Australia Between 2020 and 2029, Using a Novel Work Utility Measure: The Productivity-Adjusted Life Year (PALY). <i>JCO Oncology Practice</i> , 2021, 17, e1803-e1810.	1.4	2
46	Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1372-1382.	0.6	2
47	BCL2 and MCL1 inhibitors for hematologic malignancies. <i>Blood</i> , 2021, 138, 1120-1136.	0.6	78
48	The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes. <i>Future Oncology</i> , 2021, 17, 2563-2571.	1.1	2
49	Post-transplant maintenance therapy for MDS and AML: a bridge too far or the beginning of a new era?. <i>Leukemia and Lymphoma</i> , 2021, 62, 3073-3077.	0.6	0
50	Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. <i>Journal of Hematology and Oncology</i> , 2021, 14, 133.	6.9	13
51	FLT3-ITD signals bad news for core binding factor acute myeloid leukemia unless trisomy 22 comes to the rescue. <i>Haematologica</i> , 2021, , .	1.7	0
52	Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. <i>Cancer Medicine</i> , 2021, 10, 6336-6343.	1.3	6
53	BCL-2 Inhibition in MDS. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S104-S106.	0.2	0
54	Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 2742-2748.	0.8	3

#	ARTICLE	IF	CITATIONS
55	Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial. <i>Haematologica</i> , 2021, 106, 3240-3244.	1.7	6
56	Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 580-597.	0.2	28
57	Clinical impact of <i>NPM1</i> -mutant molecular persistence after chemotherapy for acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 5107-5111.	2.5	25
58	6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy. <i>Blood Cancer Journal</i> , 2021, 11, 163.	2.8	17
59	An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL. <i>Blood Advances</i> , 2021, 5, 5574-5583.	2.5	6
60	Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. <i>Lancet Oncology</i> , 2021, 22, 1597-1608.	5.1	90
61	New Drugs Bringing New Challenges to AML: A Brief Review. <i>Journal of Personalized Medicine</i> , 2021, 11, 1003.	1.1	5
62	Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. <i>Lancet Haematology</i> , 2021, 8, e922-e933.	2.2	27
63	A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 1261-1261.	0.6	1
64	Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy. <i>Blood</i> , 2021, 138, 36-36.	0.6	0
65	High Sensitivity Detection of <i>FLT3</i> -ITD Measurable Residual Disease By Deep Sequencing Prior to Hematopoietic Cell Transplant Is Highly Prognostic for Outcome in Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 2364-2364.	0.6	0
66	Preliminary Results from a Phase 1b Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS). <i>Blood</i> , 2021, 138, 1283-1283.	0.6	3
67	Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission. <i>Internal Medicine Journal</i> , 2021, 51, 1954-1958.	0.5	0
68	An Australasian Leukemia Lymphoma Group (ALLG) Phase 2 Study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly (INTERVENE) Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 368-368.	0.6	1
69	Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents. <i>Blood</i> , 2021, 138, 3677-3677.	0.6	5
70	Outcomes for Patients with Late-Stage Mutant-IDH2 (m-IDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial. <i>Blood</i> , 2021, 138, 1243-1243.	0.6	9
71	Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. <i>Nature Cancer</i> , 2021, 2, 1204-1223.	5.7	42
72	A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53-Mutant Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 3426-3426.	0.6	9

#	ARTICLE	IF	CITATIONS
73	Pharmacological Reduction of Mitochondrial Iron in AML Triggers a BAX/BAK Dependent Non-Canonical Cell Death Synergistic with Venetoclax. <i>Blood</i> , 2021, 138, 267-267.	0.6	0
74	Outcomes in Patients with Poor-Risk Cytogenetics with or without <i>TP53</i> Mutations Treated with Venetoclax Combined with Hypomethylating Agents. <i>Blood</i> , 2021, 138, 224-224.	0.6	16
75	A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined with Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 3424-3424.	0.6	1
76	Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant <i>IDH2</i> (<i>m IDH2</i>) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC). <i>Blood</i> , 2021, 138, 1244-1244.	0.6	1
77	Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory <i>mIDH1</i> Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 2351-2351.	0.6	3
78	Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program. <i>Blood</i> , 2021, 138, 4669-4669.	0.6	10
79	OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2021, 138, 2314-2314.	0.6	1
80	Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with <i>mIDH1</i> Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 698-698.	0.6	7
81	A Phase-Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT3-ITD and CBL-Mutant Acute Myeloid Leukemia (PON-AZA study). <i>Blood</i> , 2021, 138, 2350-2350.	0.6	4
82	Treatment practice and outcomes in <i>FLT3</i> -mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals. <i>Leukemia and Lymphoma</i> , 2020, 61, 848-854.	0.6	3
83	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020, 4, 4945-4954.	2.5	34
84	Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 3506-3517.	0.8	112
85	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2020, 383, 617-629.	13.9	1,407
86	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , 2020, 7, e601-e612.	2.2	56
87	Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models. <i>Blood Advances</i> , 2020, 4, 5062-5077.	2.5	6
88	New directions for emerging therapies in acute myeloid leukemia: the next chapter. <i>Blood Cancer Journal</i> , 2020, 10, 107.	2.8	96
89	Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. <i>New England Journal of Medicine</i> , 2020, 383, 2526-2537.	13.9	265
90	AML-062: Long-Term Follow-Up of a Phase 1/2 Study of Venetoclax (VEN) Plus Low-Dose Cytarabine (LDAC) in Previously Untreated Older Adults with Acute Myeloid Leukemia (AML). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S178.	0.2	2

#	ARTICLE	IF	CITATIONS
91	RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. <i>Blood Advances</i> , 2020, 4, 1131-1144.	2.5	102
92	Cotargeting BCL-2 and MCL-1 in high-risk B-ALL. <i>Blood Advances</i> , 2020, 4, 2762-2767.	2.5	28
93	MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia. <i>Future Oncology</i> , 2020, 16, 807-815.	1.1	53
94	MDM2 inhibition: an important step forward in cancer therapy. <i>Leukemia</i> , 2020, 34, 2858-2874.	3.3	207
95	Targeting MCL-1 in hematologic malignancies: Rationale and progress. <i>Blood Reviews</i> , 2020, 44, 100672.	2.8	135
96	Androgens stimulate erythropoiesis through the DNA-binding activity of the androgen receptor in non-hematopoietic cells. <i>European Journal of Haematology</i> , 2020, 105, 247-254.	1.1	8
97	How I treat acute myeloid leukemia in the era of new drugs. <i>Blood</i> , 2020, 135, 85-96.	0.6	172
98	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020, 135, 371-380.	0.6	127
99	Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. <i>Blood</i> , 2020, 135, 791-803.	0.6	412
100	Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations. <i>Blood</i> , 2020, 136, 8-10.	0.6	11
101	Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study. <i>Blood</i> , 2020, 136, 1-2.	0.6	54
102	Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 7-8.	0.6	13
103	BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 9-10.	0.6	4
104	Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study. <i>Blood</i> , 2020, 136, 55-57.	0.6	40
105	CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial. <i>Blood</i> , 2020, 136, 32-33.	0.6	12
106	The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3-ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16). <i>Blood</i> , 2020, 136, 16-18.	0.6	3
107	Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. <i>Blood</i> , 2020, 135, 2137-2145.	0.6	470
108	Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML). <i>Journal of Clinical Oncology</i> , 2020, 38, 7501-7501.	0.8	29

#	ARTICLE	IF	CITATIONS
109	A phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (VIALE-C): A six-month update.. Journal of Clinical Oncology, 2020, 38, 7511-7511.	0.8	10
110	Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.. Journal of Clinical Oncology, 2020, 38, 7513-7513.	0.8	2
111	Health-related quality of life (HRQoL) in the phase III QUAZAR-AML-001 trial of CC-486 as maintenance therapy for patients with acute myeloid leukemia (AML) in first remission following induction chemotherapy (IC).. Journal of Clinical Oncology, 2020, 38, 7533-7533.	0.8	4
112	Timing of response to venetoclax combination treatment in older patients with acute myeloid leukemia.. Journal of Clinical Oncology, 2020, 38, 7531-7531.	0.8	0
113	CC-486 is safe and well-tolerated as maintenance therapy in elderly patients (≥75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: Results from the phase III QUAZAR AML-001 trial.. Journal of Clinical Oncology, 2020, 38, 7530-7530.	0.8	1
114	Venetoclax Exposure-Efficacy and Exposure-Safety Relationships in Subjects with Treatment-Naïve Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy. Blood, 2020, 136, 52-52.	0.6	0
115	Peripheral Blood CD34+ Donor Chimerism Is Superior to CD3+ Donor Chimerism for Predicting Relapse Following Allogeneic Stem Cell Transplantation for Myeloid Malignancies. Blood, 2020, 136, 47-48.	0.6	0
116	Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose. Blood, 2020, 136, 40-42.	0.6	7
117	Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine. Blood, 2020, 136, 33-35.	0.6	1
118	Chromosomal Abnormalities and Prognosis in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. Journal of Clinical Oncology, 2019, 37, 2632-2642.	0.8	77
119	BCL-2 family protein BOK is a positive regulator of uridine metabolism in mammals. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15469-15474.	3.3	31
120	Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia. Cell Stem Cell, 2019, 25, 258-272.e9.	5.2	60
121	Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?. Cancer Discovery, 2019, 9, 998-1000.	7.7	5
122	Incorporating Precision BH3 Warheads Into the Offensive Against Acute Myeloid Leukemia. Journal of Clinical Oncology, 2019, 37, 1785-1789.	0.8	2
123	New drugs creating new challenges in acute myeloid leukemia. Genes Chromosomes and Cancer, 2019, 58, 903-914.	1.5	39
124	Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nature Genetics, 2019, 51, 694-704.	9.4	97
125	Maintenance therapy for AML: are we there yet?. Blood, 2019, 133, 1390-1392.	0.6	8
126	Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of Clinical Oncology, 2019, 37, 1277-1284.	0.8	494

#	ARTICLE	IF	CITATIONS
127	Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2214-2222.	0.6	40
128	Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 3-12.	0.7	12
129	Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 905-917.	3.3	126
130	Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. <i>Blood</i> , 2019, 133, 7-17.	0.6	1,254
131	Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany. <i>Blood</i> , 2019, 134, 3893-3893.	0.6	1
132	Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 2648-2648.	0.6	3
133	Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , 2019, 134, 231-231.	0.6	23
134	Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine. <i>Blood</i> , 2019, 134, 674-674.	0.6	15
135	A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 568-568.	0.6	43
136	A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART [®] Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2662-2662.	0.6	11
137	Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study. <i>Blood</i> , 2019, 134, 462-462.	0.6	5
138	Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3897-3897.	0.6	5
139	Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE [®] (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 833-833.	0.6	55
140	Phase 1b Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 570-570.	0.6	64
141	Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study. <i>Blood</i> , 2019, 134, 643-643.	0.6	37
142	The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission. <i>Blood</i> , 2019, 134, LBA-3-LBA-3.	0.6	68
143	MIRROS: An ongoing randomized phase 3 trial of idasanutlin + ARA-C in patients with relapsed or refractory acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS7063-TPS7063.	0.8	8
144	Targeting Aurora Kinase B with AZD2811 Enhances Venetoclax Activity in TP53-Mutant AML. <i>Blood</i> , 2019, 134, 3930-3930.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Inhibition of Endosteal Vascular Niche Remodeling Rescues Hematopoietic Stem Cell Loss in AML. <i>Cell Stem Cell</i> , 2018, 22, 64-77.e6.	5.2	249
146	Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. <i>Lancet Oncology</i> , The, 2018, 19, 216-228.	5.1	551
147	Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-high-dose cytarabine. <i>European Journal of Haematology</i> , 2018, 101, 174-184.	1.1	9
148	Time to repeat and replace response criteria for acute myeloid leukemia?. <i>Blood Reviews</i> , 2018, 32, 416-425.	2.8	51
149	Phase 1b study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 493-496.	0.6	5
150	Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. <i>Leukemia</i> , 2018, 32, 303-312.	3.3	123
151	Therapy-related acute myeloid leukaemia and myelodysplastic syndrome in Victoria, Australia 2003-2014. <i>Internal Medicine Journal</i> , 2018, 48, 822-829.	0.5	7
152	BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. <i>Cancer Cell</i> , 2018, 34, 879-891.	7.7	250
153	AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. <i>Cancer Discovery</i> , 2018, 8, 1582-1597.	7.7	310
154	Cytogenetic and Molecular Drivers of Outcome with Venetoclax-Based Combination Therapies in Treatment-Naïve Elderly Patients with Acute Myeloid Leukemia (AML). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S202.	0.2	5
155	Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies. <i>Blood Cancer Journal</i> , 2018, 8, 84.	2.8	5
156	High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2018, 8, 68.	2.8	36
157	FLT3mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 2800-2800.	0.6	6
158	FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Aynndrome (MDS): Results from a Phase 1 Study. <i>Blood</i> , 2018, 132, 1452-1452.	0.6	16
159	Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy. <i>Blood</i> , 2018, 132, 285-285.	0.6	29
160	Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy. <i>Blood</i> , 2018, 132, 284-284.	0.6	30
161	Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7010-7010.	0.8	7
162	Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7082-TPS7082.	0.8	3

#	ARTICLE	IF	CITATIONS
163	Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB. <i>Blood</i> , 2018, 132, 5241-5241.	0.6	0
164	Improving the Transition to Palliative Care for Patients With Acute Leukemia. <i>Cancer Nursing</i> , 2017, 40, E17-E23.	0.7	4
165	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2017, 376, 836-847.	13.9	1,443
166	â€œDid He Who Made the Lamb Make Thee?â€™™ New Developments in Treating the â€œFearful Symmetryâ€™™ of Acute Myeloid Leukemia. <i>Trends in Molecular Medicine</i> , 2017, 23, 264-281.	3.5	4
167	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 454-464.	13.9	1,628
168	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. <i>Blood</i> , 2017, 129, 2882-2895.	0.6	74
169	Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2017, 177, 328-330.	1.2	4
170	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 424-447.	0.6	4,375
171	Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia. <i>Blood</i> , 2017, 129, 771-782.	0.6	67
172	Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. <i>Blood</i> , 2017, 130, 2469-2474.	0.6	110
173	Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 1678-1685.	0.8	14
174	Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes. <i>Blood</i> , 2017, 130, 890-890.	0.6	41
175	The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study. <i>Oncotarget</i> , 2017, 8, 52269-52280.	0.8	20
176	Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. <i>Future Oncology</i> , 2016, 12, 293-302.	1.1	36
177	KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. <i>Leukemia Research</i> , 2016, 50, 123-131.	0.4	50
178	The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. <i>Science Translational Medicine</i> , 2016, 8, 339ra69.	5.8	140
179	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. <i>Nature</i> , 2016, 538, 477-482.	13.7	830
180	Isavuconazole as salvage therapy for mucormycosis. <i>Medical Mycology Case Reports</i> , 2016, 11, 36-39.	0.7	34

#	ARTICLE	IF	CITATIONS
181	Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics. <i>Cancer Cell</i> , 2016, 29, 145-158.	7.7	93
182	PUMA promotes apoptosis of hematopoietic progenitors driving leukemic progression in a mouse model of myelodysplasia. <i>Cell Death and Differentiation</i> , 2016, 23, 1049-1059.	5.0	15
183	The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells. <i>Leukemia</i> , 2016, 30, 163-172.	3.3	69
184	Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥ 65 Years with Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 102-102.	0.6	40
185	Phase 1b/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥ 65 with acute myelogenous leukemia.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7007-7007.	0.8	22
186	Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients ≥ 65 years ineligible for standard induction therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7009-7009.	0.8	33
187	Hypermethylation of GADD45A Defines a Methylation Profile Distinct to Mutant IDH1/2, and Correlates with More Aggressive AML. <i>Blood</i> , 2016, 128, 2877-2877.	0.6	0
188	Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival. <i>Blood</i> , 2016, 128, 338-338.	0.6	0
189	Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice. <i>Haematologica</i> , 2015, 100, 914-926.	1.7	51
190	Immunological markers for prognostication in cytogenetically normal acute myeloid leukemia. <i>American Journal of Hematology</i> , 2015, 90, E219-20.	2.0	2
191	Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation. <i>Transfusion</i> , 2015, 55, 2709-2713.	0.8	13
192	Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2015, 169, 199-210.	1.2	29
193	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 1025-1036.	5.1	129
194	Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML. <i>Blood</i> , 2015, 125, 2815-2824.	0.6	47
195	Protocol of a multi-centre randomised controlled trial of a web-based information intervention with nurse-delivered telephone support for haematological cancer patients and their support persons. <i>BMC Cancer</i> , 2015, 15, 295.	1.1	17
196	Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 6280-6296.	1.4	34
197	ABT-199 partners with azacitidine to contest myeloid malignancies. <i>Leukemia and Lymphoma</i> , 2015, 56, 8-9.	0.6	1
198	Comparison of Cyclophosphamide/Total Body Irradiation (Cy/TBI) and Etoposide/Total Body Irradiation (Etop/TBI) Conditioned Allogeneic Stem Cell Transplant (alloHSCT) for Adult Acute Lymphoblastic Leukaemia (ALL), Data from an Australian Tertiary Care Centre. <i>Blood</i> , 2015, 126, 5543-5543.	0.6	1

#	ARTICLE	IF	CITATIONS
199	The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) Placebo-Controlled Double-Blind Trial (CALGB 10603/PATENT/ALLIANCE 1). Blood, 2015, 126, 6-6.	0.6	104
200	An international phase 3 randomized, placebo-controlled study of CC-486 (oral azacitidine) maintenance therapy in patients with acute myeloid leukemia (AML) in complete remission (CR): The Quazar AML maintenance trial.. Journal of Clinical Oncology, 2015, 33, TPS7097-TPS7097.	0.8	0
201	Prognostic Markers in Core-Binding Factor Acute Myeloid Leukaemia. Blood, 2015, 126, 2599-2599.	0.6	0
202	Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer Journal, 2014, 4, e170-e170.	2.8	80
203	Reducing TNF Receptor 2+ Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients. Clinical Cancer Research, 2014, 20, 724-735.	3.2	76
204	Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia. Blood Cancer Journal, 2014, 4, e237-e237.	2.8	3
205	Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma. Blood Cancer Journal, 2014, 4, e213-e213.	2.8	10
206	Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia. Internal Medicine Journal, 2014, 44, 757-763.	0.5	8
207	Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. American Journal of Hematology, 2014, 89, 795-802.	2.0	63
208	Author reply. Internal Medicine Journal, 2014, 44, 825-825.	0.5	0
209	Optimal approach for high-risk acute promyelocytic leukemia. Current Opinion in Hematology, 2014, 21, 102-113.	1.2	9
210	Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care. Best Practice and Research in Clinical Haematology, 2014, 27, 39-52.	0.7	13
211	Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia. Leukemia, 2014, 28, 2005-2015.	3.3	43
212	KB004, a Novel Non-Fucosylated Humanized Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies. Blood, 2014, 124, 3756-3756.	0.6	3
213	Eradication of Acute Myeloid Leukemia Is Enhanced By Combined Bcl-2 and Mcl-1 Targeting. Blood, 2014, 124, 988-988.	0.6	2
214	The Significance of GADD45A Promoter DNA Hypermethylation in AML: Association with IDH1/2 and TET2 Mutation. Blood, 2014, 124, 69-69.	0.6	0
215	Cardiac Imaging in FIP1L1-PDGFR. Journal of the American College of Cardiology, 2013, 62, 1304.	1.2	1
216	Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood, 2013, 122, 738-748.	0.6	53

#	ARTICLE	IF	CITATIONS
217	Improving the transition of highly complex patients into the community: impact of a pharmacist in an allogeneic stem cell transplant (SCT) outpatient clinic. <i>Supportive Care in Cancer</i> , 2013, 21, 3491-3495.	1.0	23
218	Effectiveness of a single fixed dose of rasburicase 3â€‰%<scp>mg</scp> in the management of tumour lysis syndrome. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 565-568.	1.1	20
219	Discovery of Potent and Selective Benzothiazole Hydrazone Inhibitors of Bcl-X_L. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 5514-5540.	2.9	60
220	Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 675-676.	0.6	2
221	Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse. <i>Leukemia and Lymphoma</i> , 2013, 54, 336-341.	0.6	13
222	Utility of a clinical risk score to identify highâ€‰risk patients with <i>de novo</i> acute myeloid leukaemia in first remission after highâ€‰dose cytarabine (Hi<scp>DAC</scp>) based induction chemotherapy. <i>British Journal of Haematology</i> , 2013, 160, 861-863.	1.2	8
223	Methylation of <i><scp>KLF</scp>5</i> contributes to reduced expression in acute myeloid leukaemia and is associated with poor overall survival. <i>British Journal of Haematology</i> , 2013, 161, 884-888.	1.2	18
224	Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus lowâ€‰dose cytosine arabinoside in elderly patients with acute myeloid leukemia. <i>Cancer</i> , 2013, 119, 2611-2619.	2.0	88
225	Highâ€‰dose cytarabine (24â€‰%g/m²) in combination with idarubicin (<scp>HiDAC</scp>â€‰3) results in high firstâ€‰cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia. <i>Internal Medicine Journal</i> , 2013, 43, 294-297.	0.5	10
226	GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations. <i>Leukemia</i> , 2013, 27, 1588-1592.	3.3	22
227	Protein Kinase Activity of Phosphoinositide 3-Kinase Regulates Cytokine-Dependent Cell Survival. <i>PLoS Biology</i> , 2013, 11, e1001515.	2.6	19
228	A Phase I Study Of KB004, a Novel Non-Fucosylated humanizedâ€™ Antibody, Targeted Against The Receptor Tyrosine Kinase EphA3, In Advanced Hematologic Malignancies. <i>Blood</i> , 2013, 122, 3838-3838.	0.6	3
229	Fli-1 Overexpression in Hematopoietic Progenitors Deregulates T Cell Development and Induces Pre-T Cell Lymphoblastic Leukaemia/Lymphoma. <i>PLoS ONE</i> , 2013, 8, e62346.	1.1	24
230	Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma Is Feasible, Efficacious and Associated With Low Transplant-Related Morbidity and Mortality. <i>Blood</i> , 2013, 122, 2128-2128.	0.6	2
231	Puma Is The Critical BH3-Only Protein Mediating Apoptosis In The Nup98-HoxD13 (NHD13) Mouse Model Of Human MDS. <i>Blood</i> , 2013, 122, 1563-1563.	0.6	0
232	Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. <i>Genes and Development</i> , 2012, 26, 120-125.	2.7	344
233	Rapid detection of FLT3 exon 20 tyrosine kinase domain mutations in patients with acute myeloid leukemia by high-resolution melting analysis. <i>Leukemia and Lymphoma</i> , 2012, 53, 1225-1229.	0.6	3
234	Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML. <i>Leukemia</i> , 2012, 26, 362-365.	3.3	4

#	ARTICLE	IF	CITATIONS
235	A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML. <i>Blood</i> , 2012, 120, 889-889.	0.6	4
236	Stage I findings of a two-stage phase II study to assess the efficacy, safety, and tolerability of barasertib (AZD1152) compared with low-dose cytosine arabinoside (LDAC) in elderly patients (pts) with acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2012, 30, 6527-6527.	0.8	1
237	Methylation of the Proximal Promoter of GADD45A Is Common in Acute Myeloid Leukemia and Is Associated with Poor Survival.. <i>Blood</i> , 2012, 120, 2396-2396.	0.6	0
238	A Regulatory Promoter Polymorphism and Hypermethylation of Intron 1 Are Associated with Reduced Expression of KLF5 and Inferior Survival in AML. <i>Blood</i> , 2012, 120, 3508-3508.	0.6	0
239	The epigenomics revolution in myelodysplasia: a clinico-pathological perspective. <i>Pathology</i> , 2011, 43, 536-546.	0.3	12
240	Use of risk stratification to guide ambulatory management of neutropenic fever. <i>Internal Medicine Journal</i> , 2011, 41, 82-89.	0.5	30
241	Use of antibacterial prophylaxis for patients with neutropenia. <i>Internal Medicine Journal</i> , 2011, 41, 102-109.	0.5	45
242	Salvaging AML with CLAG: Novel option, or more of the same?. <i>Leukemia Research</i> , 2011, 35, 297-298.	0.4	2
243	Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study. <i>Blood</i> , 2011, 118, 1529-1529.	0.6	1
244	Azacitidine in Combination with the mTOR Inhibitor Everolimus in Relapsed and Refractory AML. <i>Blood</i> , 2011, 118, 2599-2599.	0.6	7
245	A Recombinant Antibody to EphA3 for the Treatment of Hematologic Malignancies: Research Update and Interim Phase 1 Study Results. <i>Blood</i> , 2011, 118, 4893-4893.	0.6	4
246	Initial Remission Duration Is the Most Important Predictor of Outcome Following FLAG-Amsacrine Salvage of AML in First Relapse,. <i>Blood</i> , 2011, 118, 3631-3631.	0.6	0
247	A Phase 1b Dose Escalation Safety Analysis of Lenalidomide and Azacitidine Maintenance Therapy for Poor Risk AML,. <i>Blood</i> , 2011, 118, 3625-3625.	0.6	1
248	Methylation of a Single CpG in the GADD45A Proximal Promoter Is Associated with Poor Survival in Acute Myeloid Leukemia,. <i>Blood</i> , 2011, 118, 3540-3540.	0.6	0
249	Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 926-927.	2.7	56
250	Structural Basis for Apoptosis Inhibition by Epstein-Barr Virus BHRF1. <i>PLoS Pathogens</i> , 2010, 6, e1001236.	2.1	99
251	Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up. <i>Bone Marrow Transplantation</i> , 2010, 45, 1154-1160.	1.3	4
252	Revisiting late relapses in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 735-736.	0.6	2

#	ARTICLE	IF	CITATIONS
253	A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML. <i>Blood</i> , 2010, 116, 3299-3299.	0.6	6
254	Clinical Activity of Azacitidine In Combination with the Oral mTOR Inhibitor Everolimus (RAD001) In Relapsed and Refractory AML: Interim Analysis of a Phase Ib/II Study. <i>Blood</i> , 2010, 116, 3301-3301.	0.6	1
255	Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2009, 50, 1964-1968.	0.6	4
256	New insights into the haemostatic function of platelets. <i>British Journal of Haematology</i> , 2009, 147, 415-430.	1.2	81
257	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the gallbladder. <i>Surgical Practice</i> , 2008, 12, 137-141.	0.1	1
258	Boosting platelet production. <i>Nature Medicine</i> , 2008, 14, 917-918.	15.2	6
259	Prosthetic pulmonary valve thrombosis in pregnancy successfully treated with thrombolysis. <i>Internal Medicine Journal</i> , 2008, 38, 142-143.	0.5	4
260	In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 17961-17966.	3.3	137
261	Bortezomib: Putting mantle cell lymphoma on death row. <i>Leukemia and Lymphoma</i> , 2008, 49, 657-658.	0.6	5
262	Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone. <i>Leukemia and Lymphoma</i> , 2007, 48, 212-213.	0.6	18
263	Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 8071-8076.	3.3	195
264	Rituximab responsive immune thrombocytopenic purpura in an adult with underlying autoimmune lymphoproliferative syndrome due to a splice-site mutation (IVS7+2 T>C) affecting the Fas gene. <i>European Journal of Haematology</i> , 2007, 79, 363-366.	1.1	14
265	The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. <i>Cancer Cell</i> , 2006, 10, 389-399.	7.7	1,149
266	Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. <i>Genes and Development</i> , 2005, 19, 1294-1305.	2.7	1,071
267	Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function. <i>Molecular Cell</i> , 2005, 17, 393-403.	4.5	1,639
268	Subversion of the Bcl-2 Life/Death Switch in Cancer Development and Therapy. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2005, 70, 469-477.	2.0	26
269	CD 138 Immunostaining of Bone Marrow Trepine Specimens Is the Most Sensitive Method for Quantifying Marrow Involvement in Patients with Plasma Cell Dyscrasias.. <i>Blood</i> , 2005, 106, 5071-5071.	0.6	0
270	Bone marrow immunohistology of plasma cell neoplasms. <i>Journal of Clinical Pathology</i> , 2003, 56, 406-411.	1.0	38

#	ARTICLE	IF	CITATIONS
271	Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/ β^2+ thalassemia. <i>Blood</i> , 2001, 97, 3998-3999.	0.6	101
272	Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 0, Publish Ahead of Print, .	0.6	3